Impact of Alzheimer's disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease
| Autor: | Steven G. Potkin, Jeffrey Veach, Richard Hartman, George T. Grossberg, Ravi Anand |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Adult
medicine.medical_specialty Activities of daily living Phenylcarbamates Rivastigmine macromolecular substances Placebo law.invention Central nervous system disease Degenerative disease Double-Blind Method Randomized controlled trial Alzheimer Disease law Internal medicine Activities of Daily Living Severity of illness medicine Humans Biological Psychiatry Aged Aged 80 and over Pharmacology Analysis of Variance business.industry Middle Aged medicine.disease Physical therapy Carbamates Alzheimer's disease business human activities medicine.drug |
| Zdroj: | Progress in Neuro-Psychopharmacology and Biological Psychiatry. 26:713-720 |
| ISSN: | 0278-5846 |
| DOI: | 10.1016/s0278-5846(02)00212-9 |
| Popis: | Objectives: To investigate the relationship between activities of daily living (ADL) impairment and Alzheimer's disease (AD) severity in mild to moderately severe AD patients receiving the cholinesterase (ChE) inhibitor rivastigmine. Methods: ADLs were evaluated using the Progressive Deterioration Scale (PDS). Disease severity was assessed with the Global Deterioration Scale (GDS). Patients were participants in one of three double-blind, placebo-controlled trials with rivastigmine. Results: Baseline PDS scores differed significantly (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect